Achieve Life Sciences, Inc. (ACHV) reported its fourth‑quarter and full‑year 2025 financial results on March 24, 2026. The company posted a net loss of $54.7 million for the year, up from a $39.8 million loss in 2024, and a Q4 net loss of $14.7 million, compared with $12.5 million in the prior year. Earnings per share were –$0.28, matching analyst expectations and indicating that the company’s cost‑control efforts have kept the loss in line with forecasts.
The company’s cash balance at year‑end was $36.4 million, a decline from $48.1 million in September 2025. With no revenue to offset operating expenses, the reduced runway underscores the need for additional financing to fund the Phase 3 vaping trial and future commercialization activities. A filing has raised substantial doubt about the company’s ability to continue as a going concern, highlighting the urgency of securing new capital.
Achieve announced a new strategic partnership with Adare Pharma Solutions to manufacture cytisinicline in the United States. The partnership is intended to reduce importation risks and lower production costs, giving the company greater control over its supply chain as it prepares for a potential launch. "Establishing U.S. manufacturing with Adare increases our confidence in our supply chain and continues our strong progress towards launch," said CEO Rick Stewart.
Regulatory progress remains a key focus. The company reiterated its 2026 guidance, maintaining a target for the second half of the year that aligns with the FDA’s June 20, 2026 PDUFA date for cytisinicline. Stewart added, "Achieve is fully committed to bringing cytisinicline to the millions of people who continue to struggle with nicotine dependence and need a new solution to help them quit. Much like GLP‑1 therapies have transformed the way obesity is treated, shifting it from a lifestyle issue to a recognized medical condition, smoking cessation deserves the same evolution." He also noted, "Achieve is not quitting on smokers or people who want to quit vaping. We are relentlessly working towards the potential approval of cytisinicline, the initiation of the Phase 3 vaping trial, and a data‑driven, highly targeted commercial launch approach."
Investor sentiment following the release was mixed. Some analysts expressed concern over the company’s shrinking cash runway and the need for future financing, while others noted that the earnings were in line with expectations and that the company’s strategic partnership and regulatory milestone provide a clear path forward.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.